公开(公告)号：US20230218735A1

公开(公告)日：2023-07-13

申请号：US18001953

申请日：2021-06-17

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Alexey Vyacheslavovitch Gribenko ,  William Carl Gruber ,  Kathrin Ute Jansen ,  Lakshmi Khandke ,  Nicholas Randolph Everard Kitchin ,  Jody Lawrence ,  Yahong Peng ,  Michael William Pride ,  Christopher Frederick Webber ,  Sabine Susanne Wellnitz ,  Zhuobiao Yi

IPC分类号： A61K39/08 ,  A61K47/26 ,  A61K9/19 ,  C07K16/12 ,  A61P31/04

CPC分类号： A61K39/08 ,  A61K47/26 ,  A61K9/19 ,  C07K16/1282 ,  A61P31/04 ,  A61K2039/55577

摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.

公开(公告)号：US20230165949A1

公开(公告)日：2023-06-01

申请号：US17821730

申请日：2022-08-23

申请人： Secretary of State for Health and Social Care ,  MicroPharm Limited

发明人： Clifford Shone ,  April Roberts ,  Helen Ahern ,  Michael Maynard-Smith ,  John Landon

IPC分类号： A61K39/08 ,  C07K14/33 ,  C07K16/12 ,  A61K38/16 ,  A61K39/40

CPC分类号： A61K39/08 ,  C07K14/33 ,  C07K16/1282 ,  A61K38/164 ,  A61K39/40 ,  C07K2317/76 ,  C07K2319/00 ,  A61K2039/505

摘要： The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C. difficile Toxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a C. difficile Toxin B. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

公开(公告)号：US20180208643A1

公开(公告)日：2018-07-26

申请号：US15924703

申请日：2018-03-19

申请人： UNIVERSITY OF MASSACHUSETTS ,  E. R. Squibb & Sons, L.L.C.

发明人： Donna M. AMBROSINO ,  Gregory J. BABCOCK ,  Teresa BROERING ,  Robert GRAZIANO ,  Hector Javier HERNANDEZ ,  Israel LOWY ,  Robert MANDELL ,  Deborah MOLRINE ,  William D. THOMAS, Jr. ,  Hui-Fen ZHANG

IPC分类号： C07K16/12 ,  A61K39/08 ,  G01N33/569 ,  C12N15/86 ,  A61K39/00 ,  A61K48/00

CPC分类号： C07K16/1282 ,  A61K39/08 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/86 ,  G01N33/56911 ,  G01N2333/33 ,  Y10S424/809 ,  A61K2300/00

摘要： Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

公开(公告)号：US20180037639A1

公开(公告)日：2018-02-08

申请号：US15717174

申请日：2017-09-27

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts

IPC分类号： C07K16/12 ,  C07K16/24

CPC分类号： C07K16/1282 ,  C07K16/241 ,  C07K2317/56 ,  C07K2317/64 ,  C07K2317/94 ,  C07K2319/50

摘要： There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.

公开(公告)号：US20180009881A1

公开(公告)日：2018-01-11

申请号：US15717230

申请日：2017-09-27

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton

IPC分类号： C07K16/12 ,  C07K16/24 ,  C07K16/28

CPC分类号： C07K16/1282 ,  A61K2039/542 ,  C07K16/241 ,  C07K16/2866 ,  C07K2317/22 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/472 ,  Y02A50/484

摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.

公开(公告)号：US09815889B2

公开(公告)日：2017-11-14

申请号：US14964763

申请日：2015-12-10

申请人： Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.

发明人： Peter H. Seeberger ,  Christopher E. Martin ,  Felix Broecker ,  Chakkumkal Anish

IPC分类号： A61K39/40 ,  C07K16/12 ,  A61K31/715 ,  C07K16/44 ,  A61K39/00

CPC分类号： C07K16/1282 ,  A61K31/713 ,  A61K31/715 ,  A61K39/40 ,  A61K2039/505 ,  C07K16/44

摘要： The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: α-L-Rhap-(1→3)-β-D-Glcp-(1→4)-[α-L-Rhap-(1→3)]-α-D-Glcp-(1→2)-α-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.

公开(公告)号：US09758805B2

公开(公告)日：2017-09-12

申请号：US14974581

申请日：2015-12-18

申请人： Merus N.V.

发明人： Cornelis Adriaan De Kruif ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC分类号： C12N15/00 ,  C12N5/07 ,  C12P21/04 ,  C12P21/00 ,  C07K16/12 ,  C07K16/26 ,  C07K16/36 ,  C07K16/46 ,  C07K16/18 ,  C07K16/28 ,  A61K39/395 ,  A61K39/40 ,  A61K39/00

CPC分类号： C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  A61K2039/507 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

摘要： The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US09714283B2

公开(公告)日：2017-07-25

申请号：US14790872

申请日：2015-07-02

申请人： ADMA Biologics, Inc.

发明人： Adam S. Grossman ,  Jerrold B. Grossman ,  James Mond ,  Dov A. Goldstein

IPC分类号： A61K39/395 ,  C07K16/06 ,  A61K39/42 ,  C07K16/08 ,  C07K16/10 ,  A61K45/06 ,  G01N33/68 ,  C07K16/12 ,  A61K39/155 ,  A61K39/00

CPC分类号： C07K16/06 ,  A61K39/155 ,  A61K39/39516 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/507 ,  C07K16/08 ,  C07K16/10 ,  C07K16/1009 ,  C07K16/1027 ,  C07K16/1203 ,  C07K16/1232 ,  C07K16/1242 ,  C07K16/1271 ,  C07K16/1275 ,  C07K16/1282 ,  C07K16/1285 ,  C07K16/1289 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/76 ,  G01N33/6854 ,  Y02A50/466 ,  Y02A50/469

摘要： The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).

公开(公告)号：USRE46376E1

公开(公告)日：2017-04-25

申请号：US14883000

申请日：2015-10-14

申请人： WYETH LLC

发明人： Annaliesa Sybil Anderson ,  Robert G. K. Donald ,  Kathrin Ute Jansen ,  Michael James Flint

IPC分类号： C12N15/70 ,  C12P21/06 ,  C07K14/33 ,  A61K39/08 ,  C12N15/74 ,  C12N9/10 ,  C12N9/99 ,  C07K16/12

CPC分类号： C07K14/33 ,  A61K39/08 ,  C07K16/1282 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/1051 ,  C12N9/99 ,  C12N15/74

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

公开(公告)号：US09631191B2

公开(公告)日：2017-04-25

申请号：US14094109

申请日：2013-12-02

申请人： Alexey Gennadievich Zdanovsky

发明人： Alexey Gennadievich Zdanovsky

IPC分类号： C12N5/10 ,  C12N15/13 ,  C12N15/85 ,  C12P21/04 ,  C12P21/08 ,  C12N15/10 ,  C12Q1/66 ,  G01N33/68 ,  C07K16/12

CPC分类号： C12N15/1037 ,  C07K16/1282 ,  C12Q1/66 ,  G01N33/6845 ,  G01N33/6854 ,  G01N2333/33

摘要： The present disclosure provides methods and compositions for the production of chimeric antibodies that specifically bind an antigen of interest.